https://scholars.lib.ntu.edu.tw/handle/123456789/554009
標題: | Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations | 作者: | Wu J.-Y. SHANG-GIN WU CHIH-HSIN YANG YIH-LEONG CHANG YEUN-CHUNG CHANG Hsu Y.-C. JIN-YUAN SHIH PAN-CHYR YANG |
公開日期: | 2011 | 卷: | 72 | 期: | 2 | 起(迄)頁: | 205-212 | 來源出版物: | Lung Cancer | 摘要: | Introduction: Erlotinib and gefitinib are tyrosine kinase (TK) inhibitors of epidermal growth factor receptor (EGFR) that are effective in treating non-small cell lung cancer (NSCLC). This study aimed to compare their clinical uses and the influence of EGFR mutation. Methods: The usages of erlotinib and gefitinib in advanced NSCLC were analyzed. Clinical data and EGFR mutational status of tumors were collected. Results: Seven hundred and sixteen (716) patients received gefitinib (n= 440) or erlotinib (n= 276) for stage IIIb or IV NSCLC. Erlotinib was prescribed more frequently than gefitinib in males (58.2% vs. 41.8%, p< 0.001), smokers (60.5% vs. 39.5%, p< 0.001), and non-adenocarcinoma (70.6% vs. 29.4%, p< 0.001). Of the 716 study patients, 327 underwent testing for EGFR mutations (170 with mutant EGFR and 157 with wild-type EGFR). Adenocarcinoma in patients with mutant EGFR and non-smoker status in patients with wild-type EGFR were associated with better overall survival after TK inhibitor treatment. In both patient groups with mutant EGFR or wild-type EGFR, the effectiveness of gefitinib and erlotinib, including drug response or overall survival, were not different. Conclusions: Our study revealed the obvious disparity in drug selection between erlotinib and gefitinib in clinical practice. Type of TK inhibitors did not influence treatment outcomes in patients with EGFR mutation or wild-type EGFR. ? 2010 Elsevier Ireland Ltd. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/554009 | ISSN: | 0169-5002 | DOI: | 10.1016/j.lungcan.2010.08.013 | SDG/關鍵字: | epidermal growth factor receptor; erlotinib; gefitinib; adult; advanced cancer; aged; article; cancer survival; drug efficacy; female; gene mutation; human; lung adenocarcinoma; lung non small cell cancer; major clinical study; male; overall survival; priority journal; smoking; treatment response; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Survival Analysis |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。